Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLLRT2: pirtobrutinib + epcoritamab versus R-(mini)-CHOP for untreated DLBCL-type Richter transformation
2024-513445-37-00Phase 3Authorised
- Sponsor
- University of Cologne
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib, epcoritamab, rituximab, cyclophosphamide, doxorubicin and 2 more in Diffuse Large B-Cell Lymphoma Richter Transformation and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by University of Cologne. Primary endpoint: Investigator-assessed progression-free survival. Planned start Jun 2026; status: authorised.
02
Drugs
pirtobrutinibepcoritamabrituximabcyclophosphamidedoxorubicin
03
Conditions
Diffuse Large B-Cell Lymphoma Richter Transformationchronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-513445-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513445-37-00.